Company intelligence / Profile preview

Crosswalk Therapeutics

Cambridge, Massachusetts, United Statescrosswalktherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Crosswalk Therapeutics is developing treatments for rare diseases, with a focus on Fabry and Pompe disease compounds acquired from Codexis in July 2024. These programs were previously part of a collaboration between Codexis and Takeda before Takeda discontinued its AAV gene therapy efforts in April 2023.

Therapeutic areas: Rare Diseases
Modalities: Gene therapyEnzyme replacement therapy
Industry: Biotech

Partnerships

Codexis (asset acquisition)

Beyond the preview

Go deeper on Crosswalk Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crosswalk Therapeutics.

Explore the full profile